Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03900949
Title Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors OHSU Knight Cancer Institute
Indications

acute myeloid leukemia

Therapies

Midostaurin

Cytarabine

Cytarabine + Gemtuzumab ozogamicin

Cytarabine + Daunorubicin + Gemtuzumab ozogamicin

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST